The influence of a new vanadium compound, bis(2,2′-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats

Hormone and Metabolic Research

Volumn 34, Issue 10, 2002, Pages 556-560

  Kordowiak, Anna M ^a   Dabros W ^b   Kajda, B ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Bis(2,2 bipyridine)oxovanadium(IV); Galactosyltransferase (GalT); Golgi Complexes; Liver; Pathology; Streptozotocin (STZ)

Indexed keywords

ANTIDIABETIC AGENT; BIS(2,2' BIPYRIDINE)OXOVANADIUM SULFATE; BIS(KOJATO)OXOVANADIUM; BIS(MALTOLATO)OXOVANADIUM; BIS(OXALATO)OXOVANADIUM; GALACTOSYLTRANSFERASE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE; 2,2' BIPYRIDINE; BIS(2,2' BIPYRIDINE)OXOVANADIUM(IV); BIS(2,2'-BIPYRIDINE)OXOVANADIUM(IV); ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL VACUOLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GOLGI COMPLEX; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SECRETORY VESICLE; STREPTOZOCIN DIABETES; ANIMAL; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; LIVER; METABOLISM; ULTRASTRUCTURE; WISTAR RAT;

ANIMALIA;

2,2'-DIPYRIDYL; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GALACTOSYLTRANSFERASES; GOLGI APPARATUS; HYPOGLYCEMIC AGENTS; LIVER; MICROSCOPY, ELECTRON; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR;

EID: 1842842886     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-35427     Document Type: Article

References (32)

1. Heyliger CE, Tahiliani AG, McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 1985; 227: 1474-1477
2. Tsiani E, Fantus IG. Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 1997; 8: 51-58
3. Domingo JL. Vanadium and diabetes. What about vanadium toxicity? Mol Cell Biochem 2000; 203: 185-187
4. Aharon Y, Mevorach M, Shamoon H. Vanadyl sulfate does not enhance insulin action in patients with type 1 diabetes. Diabetes Care 1998; 21: 2194-2195
5. Cam MC, Brownsey RW, McNeill JH. Mechanisms of vanadium action: Insulin-mimetic or insulin-enhancing agent. Can J Physiol Pharmacol 2000; 78: 829-847
6. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: In vivo and in vitro studies. Metabolism 2000; 49: 400-410
7. Badmaev V, Prakash S, Majeed M. Vanadium: A review of its potential role in the fight against diabetes. J Alternat Complement Med 1999; 5: 273-291
8. Crans DC. Chemistry and insulin-like properties of vanadium(IV) and vanadium(V) compounds. J Inorg Biochem 2000; 80: 123-131
9. Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signalling pathways: Evidence for preferention enhancement of metabolic vs. mitogenic effects. Mol Cell Biochem 1998; 182: 109-119
10. Cam MC, Li WM, McNeill JH. Partial preservation of pancreatic beta cells by vanadium. Evidence for long-term amelioration of diabetes. Metabolism 1997; 46: 769-778
11. Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E. Treatment of diabetes with vanadium salts: General overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diabetes Metab Res Rev 2001; 17: 55-66
12. Yuen VG, Caravan P, Gelmini L, Glover N, McNeill JH, Setyawati IA, Zhou R, Orvig C. Glucose lowering properties of vanadium compounds. Comparison of coordination complexes with maltol or kojic acid as ligands. J Inorg Biochem 1997; 68: 108-116
13. Da̧broś W, Dziga D, Gryboś R, Kordowiak AM. Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone. Path Res Pract 2000: 196: 561-568
14. Da̧broś W, Kordowiak AM, Dziga D, Gryboś R. Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes. Pol J Pathol 1998; 49: 67-76
15. 2O. Part 1. One-week treatment with vanadium compound. Pol J Pathol 2000: 1: 9-16
16. Woo LCY, Yuen VG, Thompson KH. Vanadyl-biquanide complexes as potential synergistic insulin mimics. J Inorg Biochem 1999; 76: 251-257
17. Yuen VG, Orvig C, McNeill JH. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can J Physiol 1995: 75: 55-64
18. Bhanot S, Girn J, Poucheret P, McNeill JH. Effects of bis(maltolato)oxovanadium(IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats. Mol Cell Biochem 1999; 202: 131-140
19. Kordowiak AM, Trzos R, Gryboś R. Insulin-like effects on liver Golgi membrane preparations of bis(oxalato)oxovanadate(IV) complex ion, a new vanadium compound. Horm Metab Res 1997: 29: 104-108
20. Kordowiak AM, Dudek B, Gryboś R. Influence of sodium(oxalato)oxovanadium(IV) on phospholipids in liver Golgi fractions from control and streptozotocin-diabetic rats. Comp Biochem Physiol Part C 2000; 125: 11-16
21. Reul BA, Amin SS, Buchet J-P, Ongemba LN, Crans DC, Brichard SM. Effects of vanadium complexes with organic ligands on glucose metabolism: A comparison study in diabetic rats. Brit J Pharmacol 1999; 126: 467-477
22. Kordowiak A, Turyna B, Kaczmarski F, Sarnecka-Keller M. Comparison of rat plasma glycoprotein composition with biochemical activity and morphology of liver Golgi apparatus in streptozotocin-diabetes treated with insulin. Folia Histochem Cytochem 1981; 19: 181-188
23. Kaczmarski F, Kordowiak A, Sarnecka-Keller M. Influence of insulin on galactosyltransferase activity and morphology of the rat liver Golgi apparatus in control and streptozotocin-diabetic rats. Path Res Pract 1981; 172: 130-137
24. 2) on streptozotocin-induced biochemical alterations of Golgi-rich membrane fraction in comparison with morphology of rat liver Golgi apparatus in situ. Path Res Pract 1986; 181: 397-402
25. Kordowiak AM, Polański M, Da̧broś W. Influence of LEPK on biochemical activity and morphology in situ of liver Golgi apparatus from control and streptozotocin-diabetic rats. Pol J Pathol 1997; 48: 87-93
26. Fleischer B. Isolation and characterisation of Golgi apparatus from rat liver. In: Fleischer S, Packer L (eds). Methods in Enzymology. New York: Acad Press Inc, 1974; 31A: 180-191
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275
28. Somogyi MJ, Nelson N. Determination of reducing sugars and carbohydrates. In: Whistler R, Wolprom R (eds). Methods in Carbohydrate Chemistry. New York, London: Acad Press Inc, 1962; 1: 380-394
29. Karnovsky MJ. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965; 27: 137A-138A
30. Venable JH, Coggeshall RA. Simplified lead citrate stain for use in electron microscopy. J Cell Biol 1965; 25: 407-408
31. Kurup S, Bhonde RR. Combined effect of nicotinamide and streptozotocin on diabetic status in partially pancreatectomized adult BALB/c mice. Horm Metab Res 2000; 32: 330-334
32. Żendzian-Piotrowska M, Bucki R, Górska M, Górski J. Diabetes affects phospholipid content in the nuclei of the rat liver. Horm Metab Res 2000; 32: 386-389